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Abstract
The leukodystrophies are a heterogeneous, often progressive group of disorders manifesting a 
wide range of symptoms and complications. Most of these disorders have historically had no 
etiologic or disease specific therapeutic approaches. Recently, a greater understanding of the 
pathologic mechanisms associated with leukodystrophies has allowed clinicians and researchers to 
prioritize treatment strategies and advance research in therapies for specific disorders, some of 
which are on the verge of pilot or phase I/II clinical trials. This shifts the care of leukodystrophy 
patients from the management of the complex array of symptoms and sequelae alone to targeted 
therapeutics. The unmet needs of leukodystrophy patients still remain an overwhelming burden. 
While the overwhelming consensus is that these disorders collectively are symptomatically 
treatable, leukodystrophy patients are in need of advanced therapies and if possible, a cure.
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1. Introduction
A greater understanding of the pathologic mechanisms associated with leukodystrophies has 
allowed clinicians and researchers to prioritize treatment strategies and advance research 
therapies in specific disorders. This shifts the care of leukodystrophy patients from the 
management of the complex array of symptoms and sequelae alone to targeted therapeutics. 
Herein we address the current state of existing and emerging therapies, as well as the 
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importance of systematic research in changing the prognostic implications of these 
disorders.
Namely, although almost all patients with leukodystrophies have certain core features that 
require symptomatic management, several leukodystrophies have specific complications that 
require special attention (Table 1). Although our list is not exhaustive we have sought to 
convey the breadth of disease-specific nuance and multisystem involvement that can be seen 
among affected individuals. We have taken care to address specific therapeutic approaches 
relevant to each disorder [1–3]. While it is hoped that additional disorders will have targeted 
therapies in the near future, at this point it is particularly important not to miss the diagnosis 
of conditions such as X-linked Adrenoleukodystrophy (X-ALD), Cerebrotendinous 
Xanthomatosis (CTX), Metachromatic Leukodystrophy (MLD) and Krabbe because there is 
some evidence that early intervention in carefully selected cases may improve outcomes. 
Finally, there are a variety of promising, disease specific therapies currently in human trials 
for several leukodystrophies, including X-ALD, MLD, Krabbe disease, Peroxisomal 
Biogenesis disorders, Pelizaeus-Merzbacher disease (PMD), Adult Polyglucosan Body 
Disease (APBD), and Aicardi-Goutières Syndrome (AGS). These modalities include 
traditional pharmaceuticals as well as the manipulation of stem cells, genes, and enzymes. 
We have made an effort to distinguish between the strategies that currently have some 
evidence of efficacy and those that are at this point purely experimental (Table 2); we must 
acknowledge that this judgment will change as new evidence emerges. Disorders with 
existing symptomatic or mechanistic approaches are addressed here in an alphabetical 
fashion.
2. X-linked Adrenoleukodystrophy (X-ALD)
X-ALD is one of the most common leukodystrophies and disease-specific management 
guidelines have recently been published [4]. X-ALD is caused by mutations in ABCD1, 
encoding the adrenoleukodystrophy protein (ALDP). This is an X-linked dominant disorder 
that results from a deficient very long-chain fatty acid transport protein on the surface of the 
peroxisome. Four primary phenotypes (asymptomatic, adrenal insufficiency, cerebral ALD, 
and adrenomyeloneuropathy) have been identified in X-ALD patients, which may overlap 
during the lifespan. All patients begin life asymptomatic and, in rare cases, may remain 
asymptomatic into the fourth decade in the case of men or the sixth decade in the case of 
women.
2.1 ALD: Recognition and Approach to Unique Clinical Features
X-ALD has several, potentially overlapping phenotypes. The phenotypes include (1) 
asymptomatic status, (2) adrenal insufficiency, (3) inflammatory cerebral demyelination 
often called cerebral X-ALD, and (4) progressive spastic paraparesis and sphincter 
dysfunction often called adrenomyeloneuropathy. Each phenotype, in effect, describes a 
specific subset of symptoms with a distinct management strategy. All X-ALD gene carriers 
are asymptomatic for at least the first few years of life, after which males should undergo 
regular serologic surveillance for adrenal insufficiency and regular radiologic surveillance 
for cerebral demyelination; both phenotypes are life-threatening but treatable if identified in 
a timely fashion. Males with an X-ALD mutation should be screened via cortisol stimulation 
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testing every 6–9 months for adrenal insufficiency. Women are typically spared adrenal 
insufficiency and cerebral demyelination. Patients who show signs of adrenal insufficiency 
should be started on corticosteroids and followed by an endocrinologist. All men and most 
women with an X-ALD mutation will eventually develop symptoms of spastic paraparesis 
and associated sphincter dysfunction during adulthood. Rehabilitation therapy and 
symptomatic treatment for spasticity, pain, and maintenance of ambulation can greatly 
enhance quality of life and prevent or mitigate early disability. Attentive urologic and 
gastroenterologic care may similarly help maintain comfort and independence and reduce 
the incidence of urinary tract infections.
In patients with cerebral X-ALD, Hematopoietic Stem Cell Transplantation (HSCT) has 
been shown to improve survival and stabilize or improve cognitive abilities, but only if 
treatment is initiated during the early stages of cerebral demyelination when the lesion is 
still relatively small [5–7], highlighting the importance of early diagnosis. Surveillance MRI 
studies are important for early identification of brain lesions, before clinical symptoms 
appear and in time for HSCT. Specific clinical and radiologic criteria have been established 
for triaging cerebral X-ALD patients who are candidates for HSCT and have been described 
in detail using established clinical and radiologic criteria that have been established for 
triaging candidates for HSCT [5]. Factors associated with favorable treatment outcomes 
include low pre-transplant Loes radiographic severity score [8], limited degree of neurologic 
disability and high neuropsychometric measures after HSCT intervention [5, 7]. The 
therapeutic benefits of HSCT in X-ALD patients are believed to arise, at least in part, 
through the replacement of the patient’s genetically deficient brain microglia with 
genetically competent microglial progenitor cells arising from the donor blood [9].
Newborn screening for X-ALD is being implemented in a growing number of US states and 
is performed through the measurement of 26:0-lyso-PC levels and the ratios of 26:0-lyso-PC 
to 20L0-lyso-PC [10]. X-ALD males, aged 3–12 years identified through newborn screening 
or as relatives of a proband, should undergo gadolinium-enhanced magnetic resonance 
imaging (MRI) of the brain every 6 months to screen for early signs of cerebral 
demyelination in order to establish the need for early intervention. Annual MRI studies 
should be considered for adolescent boys and adults, who are at slightly lower risk for 
developing the cerebral ALD phenotype, Many practitioners continue to screen adult males 
yearly, though the incidence of development of cerebral X-ALD in adults is less well 
known. Among X-ALD men over 50 years and X-ALD women (heterozygotes) of any age, 
the onset of the cerebral and/or adrenal insufficiency phenotypes are uncommon, suggesting 
that routine surveillance screening for these individuals is probably unnecessary.
2.2 ALD: Emerging Therapies & Clinical Trials
In boys who have not yet developed cerebral ALD, daily consumption of Lorenzo’s Oil, a 
mixture of oleic and erucic acid, in combination with dietary restriction of very long chain 
fatty acids, may help mitigate the risk of developing cerebral demyelination [11]. The oil 
acts as a competitive inhibitor of endogenous very long chain fatty acid production [12]. Use 
of Lorenzo’s Oil appears to offer a modest reduction in the risk of developing cerebral X-
ALD, although it has no impact on the progression of cerebral X-ALD once the disease 
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process has begun [11]. Its consumption carries health risks [13] and it’s availability in the 
US is currently restricted to X-ALD boys aged 3–10 under an expanded access trial (Clinical 
Trials.gov, NCT02233257).
A pilot phase trial using sobetirome, a thyromimetic, synthetic structural analogs of thyroid 
hormone that mimic tissue-restricted thyroid hormone actions [14] is in preparatory phases 
(ClinicalTrials.gov, NCT01787578) based on the molecule’s ability to upregulate ABCD2, 
whose genetic expression can help metabolize very long chain fatty acids [15]. Sobetirome 
showed efficacy and safety, indicating that it has been well tolerated at all doses studied.
Lentiviral-based gene therapy has shown early promise in X-ALD [16]. This technology 
involves the ex-vivo transduction of autologous HSCs with a human immunodeficiency 
virus type 1-derived vector. This retroviral vector targets microglial precursors, with no 
evidence of insertional mutagenesis, which can trigger leukemia and has the advantage of 
theoretically eliminating the risk of graft-versus host disease. Lentiviral ALD gene therapy 
has shown encouraging results in ALD patients where its use has resulted in polyclonal 
hematopoietic repopulation, stable transgene expression, and stabilization or reversal of 
demyelination [9] and is entering phase II/III clinical trials (ClinicalTrials.gov identifier: 
NCT01896102).
3. Adult Polyglucosan Body Disease (APBD)
APBD is one of relatively few adult-onset leukodystrophies. Symptoms usually appear in 
the 5th or 6th decade with progressive spastic paraparesis, sphincter dysfunction, and 
ascending peripheral neuropathy. The affected gene (GBE1) encodes a glycogen branching 
enzyme whose dysfunction leads to the accumulation of polyglucosan bodies in the central 
and peripheral nerves. Studies into the effectiveness of anaplerotic therapy in APBD are 
currently ongoing (ClinicalTrials.gov Identifier: NCT00947960). The implementation of 
triheptanonin, a 7-carbon triglyceride, is suspected to be an efficient substrate to the citric 
acid cycle to correct the resultant energy deficit [17]. This may be an important therapy 
which may prove beneficial in slowing the clinical course of these patients.
4. Aicardi–Goutières syndrome (AGS)
AGS is a devastating neurologic disorder that primarily affects patients in the first year of 
life. AGS is characterized, in part, by a calcifying microangiopathy and elevated cerebral 
spinal fluid (CSF) α-interferon (IFNα) levels that usually presents in the first year of life. 
The seven AGS related genes (TREX1, RNASEH2A/B/C, SAMHD1, ADAR1 and IFIH1) are 
associated with genome surveillance, integrity and damage repair. Pathogenic mutations 
appear to result in the aberrant accumulation of RNA: DNA (ribonucleic acid: 
deoxyribonucleic acid) hybrids and other immunogenic nucleic acid structures within the 
cell [18–21]. The discovery of elevated IFNα in CSF has prompted further research into the 
autoimmune complications associated with AGS.
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4.1 AGS: Recognition and Approach to Unique Clinical Features
AGS patients share many common features with those affected by systemic lupus 
erythematosus (SLE), and rare cases of SLE have been found to be associated with TREX1 
mutations. All AGS patients should be monitored and symptomatically treated for skin 
inflammation (e.g. chilblains), arthritis, inflammatory bowel disease, hematologic 
complications, and cardiomyopathy [22]. AGS patients with a SAMHD1 mutation are at risk 
high risk of developing potentially life-threatening complications from large vessel 
vasculitis; consideration should be given for both radiologic and serologic screening in these 
individuals. Many AGS patients exhibit a range of endocrine dysfunction (e.g. 
hypothyroidism) that may benefit from periodic screening and supplementation when 
indicated. Systemic immunosuppressive regimens (e.g. corticosteroids) have been employed 
as part of symptom management for AGS, but have not yet demonstrated definite 
improvement in neurologic symptoms [23].
4.2 AGS: Emerging therapies have not yet entered clinical trials
Experiments in the murine model of AGS have demonstrated over-accumulation of 
endogenous retro elements [24, 25] while SAM domain and HD domain-containing protein 
1 (SAMHD1) have been shown to be a dominant suppressor of Long Interspersed Element 1 
(LINE-1). AGS-related mutations compromise the potency of SAMHD1 against LINE-1 
retrotransposition [26]. Within the murine model of AGS, the use of reverse transcriptase 
inhibitors presumably targeting production of endogenous retroelements has been studied 
with promising results [27]. Significant work is still necessary to better understand the 
mechanisms of this disorder but efforts are underway to test the use of antiretroviral therapy 
in AGS patients.
5. Alexander disease (AxD)
AxD results from a mutation in the gene encoding glial fibrillary acidic protein (GFAP). In 
classical (i.e. Type I) AxD, symptoms of macrocephaly, seizure, and spasticity appear in 
infancy. Substantial accumulation of the mutated GFAP may also result in obstruction of 
CSF pathways and hydrocephalus [28]. Routine monitoring for this complication 
Papilledema, headache, or changes in vision or behavior can aid in the diagnosis of this 
complication. Neurosurgical intervention should be considered on case-by-case basis.
Some individuals with GFAP mutations may present in adolescence or adulthood (i.e. Type 
II AxD). Unique symptoms may include bulbar dysfunction (e.g. dysphonia, palatal 
myoclonus), autonomic dysfunction, and sleep apnea [28]. Treatment of these latter two 
symptoms may help alleviate encephalopathy and enhance quality of life.
6. Canavan disease
Canavan disease is characterized by progressive spongiform degeneration of the brain 
caused by a deficiency of the aspartoacyclase, which is necessary for brain metabolism of N-
acetyl aspartic acid (NAA) [29]. Onset is typically in the first year of life and current 
treatment is supportive. In the first gene therapy trial in Canavan disease, intraventricular 
delivery of liposome-encapsulated plasmid DNA was able to produce a transient decrease in 
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NAA accumulation, and MRI scans suggested new myelination in one of the two patients 
[30]. However, results of a phase I/II clinical trial testing intraparenchymal gene delivery 
with a recombinant adeno-associated virus serotype 2 (AAV2) vector have been more 
promising. Treated children showed decreased brain NAA concentrations, MRI changes 
suggesting more normal myelination and stabilization of brain atrophy, and evidence for 
improved clinical status on long-term follow-up [31].
7. Cerebrotendinous Xanthomatosis (CTX)
CTX is an autosomal recessive inherited lipid storage disorder that results from a genetic 
mutation in CYP27A1. CTX results from a deficiency in 27-hydroxylase, a mitochondrial 
enzyme responsible for an early step in bile acid synthesis, and is uniquely characterized by 
high levels of serum cholestanol and bile acids that deposit in the brain, lens, and tendons. 
Clinical symptoms manifest in early childhood as cataracts and diarrhea. It is only later in 
life that patients show psychomotor decline, and the typical tendon xanthomas. Daily oral 
supplementation with 750mg of chenodeoxycholic acid, a bile salt, typically corrects the 
biochemical abnormalities and may reverse some clinical symptoms [32, 33]. Some 
experience suggests that earlier treatment initiation may correlate with better outcomes [34]. 
Oral statins are often included in the CTX treatment regimen, although their clinical benefit 
is unknown.
8. Hypomyelination with Brain Stem and Spinal cord abnormalities and leg 
spasticity (HBSL)
HBSL is the result of mutations in DARS, a cytoplasmic tRNA synthetase gene. HBSL 
patients present with a broad phenotypic spectrum characterized by focal cerebral white 
matter abnormalities and spinal cord signal abnormalities [35]. Interestingly partial 
responsiveness to steroids in a number of HBSL patients with subacute disease onset 
suggests that steroids may be a therapeutic avenue that should be further studied in this 
condition [35]. Certain tRNA synthetases have non-canonical functions in biological 
processes such as angiogenesis, regulation of gene transcription, and RNA splicing [36]. 
These non-canonical tRNA synthetase functions are conserved across the complete 
phylogeny of animals, and are now established as playing key roles in a number of 
pathophysiological processes [36]. DARS specifically, is one of nine cytoplasmic tRNA 
synthetases that make up the multi-synthetase complex (MSC) which facilitates gene-
specific translational silencing of inflammation-related mRNAs. While these mechanisms 
and functions must be studied further to elucidate why individuals appear responsive and 
what their clinical response is, it provides an interesting basis for compassionate care 
treatment in these patients.
9. Krabbe Disease
9.1 Krabbe: Recognition and Approach to Unique Clinical Features
Most individuals with Krabbe disease typically experience severe neurological disturbances. 
Krabbe Disease results from pathogenic mutations in the GALC gene which encodes the 
lysosomal enzyme galactosylceramidase. Most Krabbe-causing mutations result in severely 
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diminished function of the enzyme. The classical presentation of Krabbe occurs in infancy 
where affected individuals manifest spasticity and irritability. Less commonly, some GALC 
mutations appear to result in a less severe attenuation of enzyme function which may lead to 
a milder phenotype. Unfortunately, genotype-phenotype correlations in Krabbe disease are 
generally inconsistent which poses a significant hurdle for treatment selection and clinical 
trial design.
9.2 Krabbe: Emerging Therapies
Early studies suggest that in carefully selected cases (e.g. “presymptomatic” infants or older 
patients with low neurologic morbidity) HSCT may help attenuate the usually rapid 
neurologic deterioration [37–39]. The presymptomatic treatment paradigm constitutes the 
argument for newborn screening for Krabbe disease, which is currently available in a small 
number of US states. Among patients with later disease onset, HSCT may also prove 
beneficial, although the rarity of these phenotypes has limited its study [37, 39]. As in MLD, 
these treatment recommendations are tempered by a lack of long-term outcome data and 
poor genotype-phenotype correlations [40–42]. Clinical staging criteria have been proposed 
for Krabbe disease [43] and may be useful in evaluating patients for HSCT [44].
Missense mutations, occurring in >60% of Krabbe patients, are predicted to generate 
misfolded proteins [45]. Misfolded proteins can be prematurely degraded, aggregate within 
the cell, or trigger an unfolded protein response [46–48]. It is estimated that just 10% of 
normal galactosylceramidase (GALC) function is necessary to avoid the neurological 
symptoms associated with Krabbe disease [49]. Thus, an intervention that restores 10% of 
missense-causing GALC function would have the potential for impacting this disease. 
Pharmacological chaperones, synthetic low molecular weight molecules that can be 
administered orally with broad body-wide distribution (including the CNS), can rescue 
function of mutant proteins by directing them into a proper conformation or cellular 
location, or protecting them from degradation [50–52]. Pharmacological chaperones that 
improve the activity of misfolded GALC are currently being screened, with α-lobeline and 
3′,4′,7-trihydroxyisoflavone recently identified candidates [53, 54].
10. Metachromatic Leukodystrophy (MLD)
10.1 MLD: Recognition and Approach to Unique Clinical Features
MLD results from a pathogenic mutation in the gene encoding either arylsulfatase A or 
saposin B, either of which results in the accumulation of toxic metabolites (i.e. sulfatides) 
within the nervous system as well as some visceral organs. As with Krabbe disease, 
enzymatic activity levels tend to correlate with age of onset and severity of symptoms with 
age of onset ranging from infancy (most common) to adulthood (rare). Although motor 
symptoms dominate early life presentation of MLD, adults often manifest with increasingly 
severe psychiatric disturbances. The gallbladder accumulates particularly high levels of 
sulfatides which may result in potentially life-threatening, but treatable gall bladder 
pathologies (e.g. gallstones, papillomatosis, cholecystitis). In rare cases, identification of 
gallbladder dysfunction prior to the onset of neurologic symptoms could provide a theoretic 
window for early intervention to mitigate neurologic sequelae of MLD [55].
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10.2 MLD: Emerging Therapies
MLD patients have been treated with HSCT [39, 42, 56, 57], although its use has been 
widely debated due to phenotypic variability, transplant-refractory peripheral neuropathy, 
high treatment-related morbidity and mortality, and limited long-term outcome data. The 
most substantial disagreement centers on the use of HSCT among very young patients with 
early disease onset (i.e. late-infantile MLD); in addition to variable neurocognitive 
outcomes, these patients typically manifest transplant-refractory neuropathy which results in 
progressive flaccid paralysis [5]. Experts do agree, however, that symptomatic children with 
the late-infantile form of MLD are poor candidates for these therapies, as are individuals 
with later onset forms of the disease who have already accrued cognitive morbidity [5, 39, 
58, 59]. Bone marrow transplantation has been shown to halt demyelination in minimally 
symptomatic patients with juvenile or adult MLD [60]. Since the initial publication of 
transplant outcomes in MLD [5], the treatment regimens have improved and there are 
indications that morbidity rates have fallen. In addition, the use of umbilical cord blood 
decreases the time between diagnosis and transplantation, improving outcomes of minimally 
symptomatic patients with late-infantile and juvenile MLD. Outcomes vary according to 
clinical status, Loes score, peripheral nerve disease and neurologic examination, with the 
best results for those with minimally symptomatic juvenile disease [40, 61–63]. Treatment 
recommendations are based on the limited long-term longitudinal outcome data currently 
available, as is the case of allogeneic HSCT for Krabbe disease patients [40–42]. The 
decision to pursue transplant among patients with these disorders can be complex and as a 
result, must be evaluated on an individual basis by a specialized and experienced center, 
prepared to provide the most up to date information and support patients with complex 
neurologic and systemic manifestations.
As therapy with HSCT has resulted in variable outcomes, Enzyme Replacement Therapy 
(ERT) is being studied under clinical trial in Europe, South America and Australia. ERT 
replaces the deficient or missing enzyme with an active enzyme, which is a recombinant 
human protein produced by gene activation technology. Therapeutic efficacy of ERT is 
thought to depend on the enzyme dose, frequency, and the disease stage at which treatment 
is initiated. Prior studies using a regular repeated intravenous delivery of recombinant 
human arylsulfatase A (rhASA) failed to show efficiency in permeating the blood-brain 
barrier [64]. Current Phase I/II studies, using an intrathecal delivery mechanism and a 
different enzyme are underway although no formal data will be available until late 2015 
(ClinicalTrials.gov Identifier NCT01510028).
Lentiviral-based gene therapy for MLD have produced above-normal enzyme activity in the 
central nervous system and halted disease progression in the first three patients, who were 
presymptomatic when treated (ClinicalTrials.gov identifier: NCT01560182)[16]. Phase I/II 
post-therapy monitoring is underway with Phase II/III studies expected to start in 2015.
11. Pelizaeus-Merzbacher Disease (PMD)
PMD results from pathogenic mutations in a gene (PLP1) that encodes proteolipid protein 
which is one of the proteins responsible for stabilizing the myelin sheath. At the cellular 
level, oligodendrocytes, astrocytes, microglia, and neurons are affected through a number of 
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mechanisms [65]. Mutations lead to a hypomyelinating leukodystrophy characterized by 
early onset nystagmus, hypotonia, and cognitive impairment progressing to ataxia and 
spasticity. The more severe, connatal form typically manifests symptoms such as seizures 
and/or stridor within the first two weeks of life.
Human Central Nervous System Stem Cell (HuCNS-SC), transplant for patients with the 
connatal form of PMD has completed one-year Phase I safety studies and is under further 
assessment in long-term follow up studies at University of California, San Francisco (UCSF) 
in partnership with StemCells, Inc. Pre-clinical studies with HuCNS-SC showed that 
transplantation in hypomyelinated shiverer mice generated new oligodendrocytes that 
produced MRI confirmed myelin [66]. The Phase I trial at UCSF transplanted HuCNS-SC 
directly into subcortical white matter tracts of four children with connatal PMD. MRI 
studies showed evidence for qualitative changes on T1- and T2-weighted imaging and 
progressive increases in fractional anisotropy on diffusion tensor imaging (DTI) [67]. 
Moreover, such DTI signal changes persisted after stopping immunosuppressive therapies. 
The preliminary clinical outcomes of the study suggest safety of this intervention in patients 
with PMD. While efficacy studies for PMD are needed, this approach establishes a 
methodology for other leukodystrophies and leukoencephalopathies that may benefit from 
the application of HuCNS-SCs, or other CNS cell types (e.g., oligodendrocyte precursors), 
through transplantation into the brain [68].
12. Peroxisomal Biogenesis Disorders
Peroxisomal Biogenesis Disorders including Zellweger spectrum disorder (ZSD) are a 
heterogeneous autosomal recessive group of disorders caused by defects in at least 13 
known peroxisomal (PEX) genes that are required for peroxisome assembly [69]. These 
gene defects result in reduced peroxisome numbers, enlarged size of remaining peroxisomes 
and loss of enzyme import functions, resulting in multiple peroxisomal enzyme deficiencies 
and multisystem defects. In general, patients with PEX gene mutations that abrogate PEX 
protein function cause the most severe form of the disease, Zellweger syndrome. However 
the presence of at least one PEX gene missense mutation, results in residual protein 
functions and a less severe phenotype [70].
Patients with the most severe form of Zellweger syndrome patients are born with neuronal 
migration defects, and do not survive past 1–2 years of age. However, the majority of ZSD 
patients do not have neuronal migration defects and may have normal brain MRI imaging 
early on, but are at risk to develop a leukoencephalopathy over time. A common mutation 
present in at least 30% of these patients is PEX1-Gly843Asp, due to a founder effect in 
persons of European ancestry [71]. Studies of this allele show that it is a misfolded and 
degraded protein amenable to recovery at the cellular level [72]. Using a phenotype based 
assay with PEX1-Gly843Asp cell lines expressing a GFP-PTS1 reporter, several chaperone 
compounds were identified that recovered peroxisome enzyme import in a drug library 
screen [73]. A clinical trial was initiated, based on the nonspecific chemical chaperone, 
betaine (ClinicalTrials.gov Identifier: NCT01838941).
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13. RNA polymerase III disorders
Patients with Pol III-related leukodystrophies commonly, but not invariably, suffer from 
hypogonadotropic hypogonadism, which often presents as delayed puberty, but may include 
growth hormone failure and/or hypothyroidism. We recommend that Poll III patients be 
assessed and followed by an endocrinologist [74]. The decision of whether or not to treat the 
hormonal deficiency should be taken on an individual basis, weighing the risks of the 
disease versus the potential benefits of the treatment.
14. Other Unique Clinical Features Can Occur in Several Leukodystrophies
14.1 Episodic deterioration during acute stress or illness may occur in several disorders
Almost all leukodystrophies may manifest acute neurologic deterioration in periods of acute 
stress, often without full recovery to premorbid baseline, however in certain disorders this is 
a classic presentation. Patients with Vanishing White Matter Disease (VWM) may present 
following febrile illness, head trauma and severe fright.[75]. Some mitochondrial disorders 
may manifest white matter abnormalities and episodic decline. Step-wise decline may also 
occur following infection in Pol III-related leukodystrophies [74] or in AGS [22], and after 
head trauma in X-ALD [76]. Therapeutic strategies for these disorders include aggressive 
infection prevention and treatment measures including frequent hand-washing, annual 
vaccinations for influenza and pneumococcus, and liberal antibiotic use. In the case of 
mitochondrial disorders, avoiding metabolic catabolism (i.e. nutritional fasting physiology) 
during periods of stress may also be appropriate [77]. Finally, greater than usual attention to 
avoid mild traumatic brain injury may also be warranted.
14.2 Dental anomalies occur in several hypomyelinating disorders
Pol III-related leukodystrophies, Cockayne syndrome, and Oculodentodigital Dysplasia 
(ODD) are three hypomyelinating leukodystrophies typically manifesting dental anomalies. 
For patients with these three hypomyelinating leukodystrophies, dental care is of utmost 
importance and regular visits to the dentist are recommended. In the Peroxisome Biogenesis 
Disorders, absence of enamel on the secondary teeth is a recurrent finding [78]. However, 
regular dental care and hygiene is important for all leukodystrophy patients as cavities and 
abscesses may go unnoticed in routine medical care and can result in severe medical 
morbidity. Thus, regular dental visits are recommended for all leukodystrophy patients.
4. Conclusion
As an entity, the leukodystrophies are a complex, often progressive group of disorders that 
can manifest a wide range of symptoms and complications. A number of these disorders 
have severe complications that must be addressed in order to improve quality of life for 
these patients. The multisystem involvements that can be seen in these disorders provide 
challenges for clinicians and care must be designed to accommodate all of the associated 
symptoms.
With the absence of a cure for most leukodystrophies, the disorders that currently have 
specific therapies and/or active clinical trials are of great importance. In many instances, 
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prompt recognition and early treatment initiation favor a better therapeutic response. 
Increased attention to the signs and symptoms of these leukodystrophies and education to 
promote early diagnosis is essential.
More recently, clinicians and researchers have been able to advance research therapies in 
specific disorders. A number of these disorders, previously untreatable, are on the verge of 
pilot or phase I/II clinical trials. Next generation sequencing technologies have finally 
provided a way to fill gaps in diagnosis-solving cases where in the past more than half of 
patients never achieved an etiologic diagnosis, findings that are important in improving 
patient care and quality of life. Early epidemiologic research has quantified the health care 
burden of these disorders, which occur cumulatively as frequently as every 1/7000 births 
and result in significant morbidity and health care expenditures [79–81]. Finally, increased 
awareness of rare disorders better positions patient centered foundations and researchers to 
advocate for the leukodystrophy community.
The unmet needs of leukodystrophy patients still remain an overwhelming burden. While the 
consensus is that these disorders collectively are symptomatically treatable, leukodystrophy 
patients are in need of advanced therapies and if possible, a cure. Collaboration is the 
cornerstone of progress in the world of rare diseases. The growth of clinical research 
networks in the field of leukodystrophies and likewise, the increasingly common alliance of 
these consortiums with patient advocacy groups also bodes well, particularly in regards to 
the need for prioritizing and measuring patient-reported outcomes. Although the rise of 
patient-powered research models has arrived at a welcome time, the heavy burden of 
weighing safety, efficacy, and trial designs at the threshold of translational-to-clinical 
medicine will continue to engage clinical investigators.
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SLE systemic lupus erythematosus
AxD Alexander disease
GFAP Growth factor associated protein
MLD Metachromatic leukodystrophy
Pol III Polymerase III
VWM Vanishing white matter disease
CTX cerebrotendinous xanthomatosis
HSCT Hematopoietic stem cell therapy
MRI Magnetic resonance imaging
CNS Central nervous system
PMD Pelizaeus-Merzbacher disease
APBD adult polyglucosan body disease
NAA N-acetyl aspartic acid
AAV2 Adeno-associated virus serotype 2
SAMHD1 SAM domain and HD domain-containing protein 1
LINE1 Long Interspersed Element 1
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2
ABCD1 ATP-binding cassette, sub-family D (ALD), member 1
GALC galactosylceramidase
HBSL hypomyelination with brain stem and spinal cord abnormalities and leg 
spasticity
ERT Enzyme Replacement Therapy
rhASA Recombinant Human Arylsulfatase A
ZSD Zellweger spectrum disorder
PEX peroxisomal
HuCNS-SC Human Central Nervous System Stem Cell
UCSF University of California, San Francisco
DTI Diffusion Tensor Imaging
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• Historically Leukodystrophies have lacked disease specific therapeutic 
approaches or technological cures
• A greater understanding of the pathologic mechanisms has advanced research in 
therapies for specific disorders
• Prompt recognition and early treatment initiation for disorders with specific 
therapies favor a better therapeutic response
• A number of disorders, previously untreatable, are on the verge of pilot or phase 
I/II clinical trials
• Leukodystrophies are a complex group of disorders for which the advancement 
of specific therapies must be prioritized
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Table 1
Examples of symptomatic therapies relevant to specific leukodystrophies
Symptom Associated Disease(s) Prevention/Treatment
Adrenal insufficiency X-ALD Annual ACTH screening; corticosteroids. Rare in X-ALD 
women.
Pathological fracture X-ALD and other non 
ambulatory patients
Calcium and vitamin D supplementation for X-ALD patients 
on corticosteroids. Monitor bone health in all leukodystrophy 
patients with impaired mobility
Inflammatory cerebral demyelination X-ALD Occurs in 40% of ALD boys between 3–12 years. HSCT 
effectively halts demyelination, but only if initiated soon after 
lesion onset. Surveillance MRIs every 6 months can detect 
demyelination at a sufficiently early stage. This phenotype also 
affects 25% of ALD men aged 12–50 years, although comorbid 
symptoms of AMN in adult men can complicate HSCT. 
Phenotype is rare among older men as well as ALD women of 
any age.
Autoimmune manifestations and large 
vessel vasculitis
AGS Patients with AGS have skin manifestations such as chilblains 
requiring specialized wound care. Additionally, 
hypothyroidism hypothesized to have an autoimmune 
mechanism is occasionally seen and TSH should be performed 
yearly to institute appropriate therapy as needed. AGS patients 
may rarely have arthropathy, autoimmune hepatitis or other 
systemic inflammatory features. AGS patients with mutations 
in SAMHD1 may have large vessel intracerebral vasculitis and 
this should be screened with neuroimaging.
Obstructive hydrocephalus AxD AxD patients should be screened and treated for obstructive 
hydrocephalus
Premature ovarian failure VWM, AARS2 related 
leukodystrophy
None known
Episodic deterioration VWM, mitochondrial, Pol III 
and more rarely in other 
leukodystrophies
Avoidance of triggers (e.g. head trauma, fevers, severe fright)
Cardiac dysfunction Mitochondrial Cardiac evaluation; pacemaker/defibrillator may be appropriate 
in some patients. Patients should be re-evaluated at intervals 
according to their needs.
Deafness Mitochondrial and 18q−in 
early stages; many 
leukodystrophies in later 
stages
Auditory evaluation; treatments limited
Hypogonadotropic Hypogonadism, 
growth hormone deficiency
Pol-III Supplemental hormonal therapies
Dental anomalies Pol-III, ODDD, Cockayne Dental care to prevent caries, consultation with an orthodontist 
as necessary. General anesthesia should be employed with 
caution if procedure is non-essential.
Hypercholestanolemia xanthoma 
formation, cataracts, psychomotor 
decline
CTX Daily supplementation with chenodeoxycholic acid normalizes 
cholestanol levels and may prevent and/or improve other 
disease manifestations, statins
Gallbladder dysfunction MLD Patients with MLD can have gallbladder involvement leading 
the feeding intolerance, hematochezia, and pain. This should be 
considered and managed in the symptomatic patient.
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